Basal cell naevus syndrome is a rare inherited disorder that causes multiple skin cancers to develop at a young age, along with jaw cysts and skeletal differences. Managing this condition requires lifelong monitoring and treatment from a team of medical specialists who work together to detect and address cancers early.

Managing a Complex Genetic Condition

Basal cell naevus syndrome, commonly known as Gorlin syndrome, presents unique challenges because it affects multiple parts of the body throughout a person’s lifetime. The main goal of treatment is to catch skin cancers as early as possible, when they’re easiest to remove, and to manage the various other features of the condition that can affect quality of life. Unlike typical skin cancer that develops in older adults after years of sun exposure, people with this syndrome often see their first basal cell carcinoma (a type of skin cancer that starts in the outer layer of skin) appearing during their teenage years or early twenties.^[1]

Treatment strategies depend heavily on several factors, including how many skin cancers develop, where they appear on the body, the person’s age, and which other features of the syndrome are present. Some people with basal cell naevus syndrome develop just a few skin cancers in their lifetime, while others may develop dozens or even hundreds. The severity varies considerably, even among family members who inherit the same genetic mutation. This variability means that treatment plans must be highly individualized and adjusted over time as the person’s condition evolves.^[2]

Because this syndrome is hereditary and affects multiple body systems, treatment requires coordination among dermatologists, oral surgeons, genetic counselors, and sometimes neurologists, ophthalmologists, and gynecologists. Medical guidelines emphasize the importance of regular screening from childhood onward to catch problems before they become serious. Early detection is particularly crucial for skin cancers on the face, as these can cause significant cosmetic concerns if allowed to grow large before treatment.^[4]

Standard Treatment Approaches

The cornerstone of managing basal cell naevus syndrome is surgical removal of skin cancers as they appear. The most common and effective approach is called Mohs surgery, a specialized technique where the surgeon removes the cancer layer by layer, examining each thin slice under a microscope until no cancer cells remain. This method has proven particularly valuable for people with this syndrome because it removes all cancer while preserving as much healthy tissue as possible. Mohs surgery achieves cure rates of 99% for basal cell carcinomas, making it the gold standard treatment when the cancers appear on cosmetically important areas like the face, ears, or neck.^[3]

When someone develops multiple basal cell carcinomas, as often happens with this syndrome, doctors may use several different removal techniques depending on the size and location of each cancer. Smaller lesions might be treated with excision, where the surgeon cuts out the cancer and some surrounding tissue, then closes the wound with stitches. Another option is curettage and electrodesiccation, a procedure that involves scraping away the cancer tissue and then using an electric current to destroy any remaining abnormal cells. For very superficial cancers, cryotherapy (freezing the tissue with liquid nitrogen) may be appropriate.^[1]

In recent years, a topical cream called imiquimod has shown promise for treating superficial basal cell carcinomas in people with basal cell naevus syndrome. Imiquimod is an immune response modifier that works by stimulating the body’s own immune system to attack cancer cells. Patients apply the cream directly to the skin cancer several times per week for several weeks. Studies have reported successful treatment of multiple basal cell carcinomas using this approach, which can be particularly helpful when someone has many small cancers that would be difficult to remove surgically. However, this treatment only works for thin, superficial cancers and isn’t appropriate for deeper or more aggressive tumors.^[9]

Beyond treating skin cancers, standard care includes managing the odontogenic keratocysts (fluid-filled growths in the jawbone) that affect up to 80% of people with the syndrome. These cysts typically appear during the teenage years or twenties and can cause swelling, tooth displacement, and sometimes pain, though they’re often discovered on routine dental X-rays before symptoms develop. Treatment involves surgical removal of the cysts, usually performed by an oral surgeon. Unfortunately, these jaw cysts tend to come back even after removal, so people need regular dental examinations and periodic panoramic jaw X-rays to monitor for recurrence.^[4]

For children with basal cell naevus syndrome, special attention focuses on screening for medulloblastoma, a type of brain cancer that can develop in early childhood. Children with mutations in the SUFU gene face an especially high risk, about 20 times higher than those with PTCH1 mutations. Guidelines recommend regular brain imaging with magnetic resonance imaging (MRI) during the first few years of life. If medulloblastoma is detected, treatment typically involves surgery to remove the tumor followed by chemotherapy. Radiation therapy to the brain is avoided when possible because of the risk of triggering multiple new skin cancers.^[2]

Preventive care is absolutely essential for people with this syndrome. Because ultraviolet light from the sun can trigger the development of basal cell carcinomas, strict sun protection becomes a daily necessity. This includes applying broad-spectrum sunscreen with at least SPF 30 every day, wearing protective clothing including wide-brimmed hats and long sleeves, seeking shade during peak sun hours, and completely avoiding tanning beds. These measures can significantly reduce the number of skin cancers that develop, though they cannot eliminate the risk entirely since the underlying genetic mutation makes the skin vulnerable even without sun exposure.^[1]

Innovative Treatments in Clinical Trials

Recent years have brought exciting developments in targeted therapies for basal cell naevus syndrome, particularly drugs that directly address the underlying genetic pathway that causes the condition. The most significant breakthrough involves medications called hedgehog pathway inhibitors. These drugs work by blocking the abnormal signaling that occurs when the PTCH1 gene isn’t functioning properly. When this gene is mutated, it cannot properly control a cellular communication pathway called the sonic hedgehog pathway, which normally regulates cell growth and division. Hedgehog inhibitors restore some of this control, preventing cancer cells from growing and multiplying.^[1]

The first hedgehog pathway inhibitor to be extensively studied in clinical trials was vismodegib. This oral medication has been tested in patients with basal cell naevus syndrome who have multiple skin cancers. Clinical trials showed that vismodegib can reduce the size of existing basal cell carcinomas and prevent new ones from forming while patients take the medication. In Phase II clinical trials involving people with this syndrome, participants experienced significant reduction in their tumor burden, with many lesions shrinking or disappearing entirely. These promising results led to regulatory approval of vismodegib for treating advanced or metastatic basal cell carcinoma in the general population.^[18]

Another hedgehog pathway inhibitor being investigated is sonidegib. Like vismodegib, this medication blocks the abnormal signaling cascade that drives tumor formation in basal cell naevus syndrome. Clinical trials have evaluated sonidegib both in patients with sporadic basal cell carcinomas and those with the genetic syndrome. Early phase trials established the safety profile and appropriate dosing, while later phase studies examined effectiveness. Results showed that sonidegib can achieve tumor response rates comparable to vismodegib, offering an alternative option for patients who need systemic therapy.^[18]

Despite their effectiveness, hedgehog pathway inhibitors come with significant side effects that limit their use. Common problems include muscle cramps, which can be severe and debilitating; loss of taste or altered taste perception; hair loss; fatigue; nausea; and weight loss. Many patients find these side effects difficult to tolerate over long periods. Additionally, when patients stop taking the medication, new skin cancers typically begin to develop again. For these reasons, doctors generally reserve hedgehog inhibitors for people who have very aggressive disease with numerous cancers that cannot be managed with surgery alone, or for cancers that have spread beyond the skin.^[18]

Researchers continue to investigate ways to improve hedgehog pathway inhibitor therapy. Current clinical trials are exploring different dosing schedules, such as intermittent treatment where patients take the medication for several months, then stop for a period before resuming. This approach might reduce side effects while maintaining effectiveness. Other studies are combining hedgehog inhibitors with other types of therapy to enhance their cancer-fighting effects or testing newer molecules that block the same pathway but might have fewer side effects.^[18]

Gene therapy represents another frontier in research, though it remains in early experimental stages for basal cell naevus syndrome. Scientists are investigating whether it might be possible to correct or compensate for the faulty PTCH1 or SUFU genes. This approach faces significant technical challenges because the genetic mutation is present in every cell of the body from conception. However, advances in gene-editing technologies like CRISPR are opening new possibilities that seemed impossible just a few years ago. Any potential gene therapy for this condition remains many years away from clinical use.^[18]

Clinical trials for basal cell naevus syndrome are being conducted at major medical centers around the world, including in the United States, Europe, and other regions. People with the syndrome who are interested in participating in research studies should discuss this option with their dermatologist or genetic counselor. Trial eligibility typically depends on factors such as the number and location of skin cancers, previous treatments received, and overall health status. Participating in clinical trials gives patients access to cutting-edge therapies while contributing to scientific knowledge that may help future generations.^[18]

Most Common Treatment Methods

• Surgical Removal
  • Mohs surgery removes cancer layer by layer with microscopic examination, achieving 99% cure rate for basal cell carcinomas
  • Standard excision involves cutting out the cancer and surrounding tissue
  • Curettage and electrodesiccation scrapes away cancer then destroys remaining cells with electric current
  • Cryotherapy freezes superficial cancers with liquid nitrogen
• Topical Medications
  • Imiquimod cream stimulates the immune system to attack superficial basal cell carcinomas
  • Applied several times weekly for several weeks
  • Particularly helpful when multiple small, superficial cancers are present
• Hedgehog Pathway Inhibitors
  • Vismodegib blocks abnormal sonic hedgehog signaling pathway
  • Sonidegib offers alternative hedgehog pathway inhibition
  • Reduces tumor size and prevents new cancer formation during treatment
  • Reserved for aggressive disease that cannot be managed with surgery
  • Significant side effects include muscle cramps, taste changes, hair loss, and fatigue
• Jaw Cyst Treatment
  • Surgical removal of odontogenic keratocysts by oral surgeon
  • Regular monitoring with panoramic dental X-rays for recurrence
• Prevention Strategies
  • Daily broad-spectrum sunscreen application with SPF 30 or higher
  • Protective clothing including wide-brimmed hats and long sleeves
  • Avoiding tanning beds completely
  • Seeking shade during peak sun hours
  • Regular skin examinations every 6 to 12 months